Marlborough, Mass. — SCIEX, a Danaher company focused on life science analytical technologies, has announced new capillary electrophoresis capabilities for its BioPhase 8800 system aimed at helping laboratories accelerate development timelines, strengthen compliance and improve automation.
The updates include BioPhase software 1.6, the BioPhase Instrument API and the Oligo 200 nt Purity and Integrity kit.
BioPhase software 1.6 adds tools intended to support regulated drug development workflows, including user management, audit trails, electronic signatures and project management capabilities.
The BioPhase Instrument API enables the BioPhase 8800 system to connect with laboratory automation environments. External software applications can use the API for remote sequence execution, real-time instrument monitoring, instrument control and automated data acquisition.
SCIEX also introduced the Oligo 200 nt Purity and Integrity kit, which expands the company’s capillary electrophoresis workflows for high-resolution analysis of single-stranded oligonucleotides of more than 200 nucleotides. The kit can also support characterization of mRNA poly(A) tails, which can play an important role in therapeutic efficacy.
“Our customers are looking to accelerate development timelines while maintaining confidence in data quality, compliance, and scalability,” said Jose Castro-Perez, Vice President, Product Management at SCIEX. “These new BioPhase 8800 system capabilities strengthen regulated workflow support, enable deeper automation integration, and expand analytical coverage for emerging oligonucleotide-based therapeutics, helping laboratories move faster from development to decision.”
SCIEX said the expanded capabilities are designed to give laboratories greater flexibility as they develop and analyze emerging oligonucleotide-based therapeutics.
The company is also presenting the new BioPhase capabilities during CE Pharm on Sept. 28, including a technical session focused on BioPhase software and the separation of oligonucleotides.
